MX2021012129A - Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales. - Google Patents

Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales.

Info

Publication number
MX2021012129A
MX2021012129A MX2021012129A MX2021012129A MX2021012129A MX 2021012129 A MX2021012129 A MX 2021012129A MX 2021012129 A MX2021012129 A MX 2021012129A MX 2021012129 A MX2021012129 A MX 2021012129A MX 2021012129 A MX2021012129 A MX 2021012129A
Authority
MX
Mexico
Prior art keywords
methods
neurodegenerative
compositions
treatment
same
Prior art date
Application number
MX2021012129A
Other languages
English (en)
Inventor
Shawn Johnstone
Robert Devita
Roulet Daniel De
Johan Bartholomeus
Randall Marcelo Chin
Nicholas Thomas Hertz
Original Assignee
Mitokinin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitokinin Inc filed Critical Mitokinin Inc
Publication of MX2021012129A publication Critical patent/MX2021012129A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se dirige a análogos de heteroarilo que contienen nitrógeno, métodos para fabricar los análogos que contienen nitrógeno y métodos para el tratamiento de trastornos relacionados con la actividad de cinasa PINK1 que incluyen, de forma no taxativa, enfermedades neurodegenerativas, enfermedades mitocondriales, fibrosis y/o cardiomiopatías con el uso de estos análogos; este resumen pretende ser una herramienta de lectura rápida para los fines de búsqueda en la técnica particular y no pretende limitar la presente invención.
MX2021012129A 2019-04-03 2020-04-03 Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales. MX2021012129A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962828995P 2019-04-03 2019-04-03
US201962879794P 2019-07-29 2019-07-29
US201962933632P 2019-11-11 2019-11-11
PCT/US2020/026732 WO2020206363A1 (en) 2019-04-03 2020-04-03 Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease

Publications (1)

Publication Number Publication Date
MX2021012129A true MX2021012129A (es) 2022-01-31

Family

ID=72666280

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012129A MX2021012129A (es) 2019-04-03 2020-04-03 Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales.

Country Status (11)

Country Link
US (1) US20220162215A1 (es)
EP (1) EP3947390A4 (es)
JP (1) JP2022527025A (es)
KR (1) KR20220004068A (es)
CN (1) CN114026093A (es)
AU (1) AU2020253561A1 (es)
BR (1) BR112021019802A2 (es)
CA (1) CA3135755A1 (es)
IL (1) IL286767A (es)
MX (1) MX2021012129A (es)
WO (1) WO2020206363A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3641545A4 (en) 2017-06-21 2021-02-24 Mitokinin, Inc. COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
WO2023023670A1 (en) * 2021-08-20 2023-02-23 Mitokinin, Inc. Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
WO2023023671A1 (en) * 2021-08-20 2023-02-23 Mitokinin, Inc. Compositions and methods for treatment of neurodegenerative and mitochondrial disease
WO2024040266A2 (en) * 2022-08-19 2024-02-22 Mitokinin, Inc. Disubstituted benzoimidazole and indole analogs as modulators of pink1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101282974A (zh) * 2005-08-04 2008-10-08 西特里斯药业公司 作为sirtuin调节剂的咪唑并吡啶衍生物
KR101389209B1 (ko) * 2006-07-18 2014-04-24 아스텔라스세이야쿠 가부시키가이샤 아미노인단 유도체 또는 그의 염
WO2014124458A1 (en) * 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
EP2818472A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
CA2939219C (en) * 2014-02-11 2023-02-28 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
JP2018537502A (ja) * 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
WO2018106818A1 (en) * 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
EA201990851A1 (ru) * 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
EP3641545A4 (en) * 2017-06-21 2021-02-24 Mitokinin, Inc. COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
IL295681A (en) * 2020-02-21 2022-10-01 Mitokinin Inc Compositions and methods of identical use for the treatment of neurodegenerative and mitochondrial diseases

Also Published As

Publication number Publication date
EP3947390A1 (en) 2022-02-09
JP2022527025A (ja) 2022-05-27
US20220162215A1 (en) 2022-05-26
CN114026093A (zh) 2022-02-08
CA3135755A1 (en) 2020-10-08
KR20220004068A (ko) 2022-01-11
BR112021019802A2 (pt) 2021-12-07
AU2020253561A1 (en) 2021-12-02
EP3947390A4 (en) 2022-11-30
IL286767A (en) 2021-12-01
WO2020206363A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
MX2021012129A (es) Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales.
SA521430638B1 (ar) H مركبات بيرميدين-2-يل أمينو-1 lrrk2 بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبية
NZ770222A (en) Bicyclic lactams and methods of use thereof
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
EA202091709A1 (ru) Ингибиторы днк-пк
EA201790817A1 (ru) 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1 для лечения болезни альцгеймера
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
EA201790818A1 (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1
EA202091708A1 (ru) Ингибиторы днк-пк
MX2022006466A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune.
PH12017501043A1 (en) 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
MX2021011574A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
ZA202210409B (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
MX2023003924A (es) Metodos de administracion de tratamiento antifibrotico.
EA201690170A1 (ru) Композиции и способы для лечения инсульта
IN2014DE00281A (es)
EA201991208A1 (ru) Способы лечения множественного остеохондроматоза (мо)